Kinase inhibitors in the treatment of renal cell carcinoma

被引：32

作者：

Larkin, James M. G. ^{[1
]}

Eisen, Tim ^{[1
]}

机构：

[1] Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2006年 / 60卷 / 03期

关键词：

renal cell carcinoma; metastatic; systemic therapy; kinase inhibition; targeted drugs;

D O I：

10.1016/j.critrevonc.2006.06.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy confers a small but significant overall survival advantage in metastatic renal cell carcinoma (RCC) but a need exists to develop more effective systemic therapies. Angiogenesis has a key role in the pathophysiology of renal cell carcinoma and vascular endothelial growth factor (VEGF) is an important mediator of this process. Sunitimb, sorafenib and axitinib are new agents which belong to a class of drugs called kinase inhibitors and inhibit the VEGF, platelet-derived growth factor (PDGF) and c-KIT receptor tyrosine kinases. Ternsirolimus inhibits the mammalian target of rapamycin (mTOR). All these agents have shown significant activity with manageable toxicity in metastatic RCC in phase 2 studies in patients generally pretreated with immunotherapy, whilst prolonged progression-free survival in a phase 3 study has been reported with sorafenib in comparison with placebo. Further phase 3 trials are recruiting and the combination of kinase inhibitors with other therapies is under investigation. (c) 2006 Elsevier Ireland Ltd. All rights reserved.

引用

页码：216 / 226

页数：11

共 97 条

[41] Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial [J].

Kris, MG ;

Natale, RB ;

Herbst, RS ;

Lynch, TJ ;

Prager, D ;

Belani, CP ;

Schiller, JH ;

Kelly, K ;

Spiridonidis, H ;

Sandler, A ;

Albain, KS ;

Cella, D ;

Wolf, MK ;

Averbuch, SD ;

Ochs, JJ ;

Kay, AC .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (16) :2149-2158

[42]

Kuenen BC, 2003, CLIN CANCER RES, V9, P1648

[43] An algorithm for approximate tandem repeats [J].

Landau, GM ;

Schmidt, JP ;

Sokol, D .

JOURNAL OF COMPUTATIONAL BIOLOGY, 2001, 8 (01) :1-18

[44]

Lara PN, 2003, CLIN CANCER RES, V9, P4772

[45] The MRC randomised-controlled trial of interferon-α, interleukin-2 and 5-fluorouracil vs interferon-α alone in patients with advanced renal cell carcinoma (RE04):: Rationale and progress [J].

Larkin, JMG ;

Gore, ME .

CLINICAL ONCOLOGY, 2005, 17 (05) :319-321

[46] IDENTIFICATION OF THE VONHIPPEL-LINDAU DISEASE TUMOR-SUPPRESSOR GENE [J].

LATIF, F ;

TORY, K ;

GNARRA, J ;

YAO, M ;

DUH, FM ;

ORCUTT, ML ;

STACKHOUSE, T ;

KUZMIN, I ;

MODI, W ;

GEIL, L ;

SCHMIDT, L ;

ZHOU, FW ;

LI, H ;

WEI, MH ;

CHEN, F ;

GLENN, G ;

CHOYKE, P ;

WALTHER, MM ;

WENG, YK ;

DUAN, DSR ;

DEAN, M ;

GLAVAC, D ;

RICHARDS, FM ;

CROSSEY, PA ;

FERGUSONSMITH, MA ;

LEPASLIER, D ;

CHUMAKOV, I ;

COHEN, D ;

CHINAULT, AC ;

MAHER, ER ;

LINEHAN, WM ;

ZBAR, B ;

LERMAN, MI .

SCIENCE, 1993, 260 (5112) :1317-1320

[47] Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 [J].

le Coutre, P ;

Kreuzer, KA ;

Pursche, S ;

von Bonin, M ;

Leopold, T ;

Baskaynak, G ;

Dörken, B ;

Ehninger, G ;

Ottmann, O ;

Jenke, A ;

Bornhäuser, M ;

Schleyer, E .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2004, 53 (04) :313-323

[48] Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth [J].

Lee, JS ;

Kim, HS ;

Kim, YB ;

Lee, MC ;

Park, CS .

JOURNAL OF SURGICAL ONCOLOGY, 2003, 84 (03) :166-172

[49] Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with Imatinib (STI-571) [J].

Leis, JF ;

Stepan, DE ;

Curtin, PT ;

Ford, JM ;

Peng, B ;

Schubach, S ;

Druker, BJ ;

Maziarz, RT .

LEUKEMIA & LYMPHOMA, 2004, 45 (04) :695-698

[50] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

← 1 2 3 4 5 6 7 8 9 10 →